摘要
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is an enveloped RNA betacoronavirus,1 that has spread globally since December 2019.As of July 22,2020,more than 14,000,000 confirmed cases and 607,781 deaths from COVID-19 have been reported to the World Health Organization from 216 areas and territories.2 Patientswithmore prominent laboratory abnormalities may develop acute respiratory distress syndrome(ARDS),which potentially leads tomultiple organ failure and death.1,3 However,at present,there are no regulatory approved antiviralmedicines,vaccines,or specific clinical treatments for COVID-19.
基金
supported by grants from the National Natural Science Foundation of China[No.81970001]
Tianjin Natural Science Foundation[20JCYBJC01250]
the Tianjin University COVID-19 Contingency fund[No.2020XY-0059].